ASCO: Early Purple data gain ground in metastatic pancreatic cancer

Purple Biotech hopes its lead asset against metastatic pancreatic cancer will one day show its true colors as a potential first-in-class drug in a larger study—but, for now, it has preliminary, midstage trial results demonstrating measurable gains in overall survival.

Presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, the late-breaking poster data from the company’s phase 2b trial also illustrated improvements in progression-free survival as well as in a diagnostic biomarker linked to pancreatic ductal adenocarcinoma.